• Enwen Wang, Hui Huang, Long Tang, Ling Tian, Liejun Yang, Sixiong Wang, and Huiwen Ma.
• Department of Palliative Treatment, Chongqing University Cancer Hospital & Chongqing Cancer Institute, Chongqing, PR China.
• Medicine (Baltimore). 2021 Sep 24; 100 (38): e27223e27223.

BackgroundThe aim of this study was to systematically evaluate the prognostic role of platelet lymphocyte ratio (PLR) in patients with melanoma through performing a meta-analysis.MethodsPubMed, EMBASE, Web of Science, and China National Knowledge Infrastructure were searched for potential studies. The basic characteristics and relevant data were extracted. Hazard ratios with 95% confidence intervals (CIs) were pooled to evaluate the prognostic role of PLR in patients with melanoma.ResultsTen studies enrolling 2422 patients were included. The pooled hazard ratios of higher PLR for overall survival and progression-free survival in melanoma were 1.70 (95% CI, 1.22-2.37) and 1.65 (95% CI, 1.10-2.47), respectively. Sensitivity analysis and subgroup analyses were also performed. No significant publication bias was observed.ConclusionOur results showed that higher PLR was associated with poorer overall survival and progression-free survival in patients with melanoma. These findings may help to determine the prognosis and explore future novel therapies based on modulating inflammation and immune responses in melanoma.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

17 keywords...

hide…